Currentmedical mutual - ohioPolicy N/A

Oral iron chelators (deferasirox, deferiprone) — Prior authorization and coverage criteria

Pharmacy benefit prior authorization and coverage criteria for oral iron chelators Exjade/Jadenu (deferasirox) and Ferriprox (deferiprone) for treatment of chronic iron overload and related indications; applies to prescribers and pharmacists managing these agents.

Policy Summary

Payermedical mutual - ohio

PolicyOral iron chelators (deferasirox, deferiprone) — Prior authorization and coverage criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateJun 19, 2025

Key ActionObtain prior authorization and document pre-treatment serum ferritin and prescribing physician specialty (hematologist) for approval.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 yearapproval duration

>1000ferritin threshold (transfusion)

>300ferritin threshold (NTDT)

≥2min age (transfusion indication)

≥10min age (NTDT)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Authorization Criteria for Oral Iron Chelators

Deferiprone (Ferriprox) Coverage

Covered when ALL of the following are met for deferiprone (Ferriprox):

Indication groups: A) Initial Therapy: patient has transfusion‑related chronic iron overload prior to starting chelation with pre‑treatment serum ferritin >1000 mcg/L AND deferiprone is prescribed by or in consultation with a hematologist. OR B) Patients currently receiving deferiprone: patient is benefiting from deferiprone therapy (e.g., reduction in serum ferritin, stable disease, reduced organ iron load) as documented by the prescribing physician.see node text

Approvals are for 1 year when criteria are met.

Brand Ferriprox exceptions: When brand Ferriprox is prescribed, approve only if ONE of the following is met: (a) patient previously failed or is intolerant to generic deferiprone tablets; OR (b) brand is requested due to a formulation difference in inactive ingredient(s) that per the prescriber would cause a significant allergy or serious adverse reaction (documentation required); OR (c) brand oral solution is required for swallowing difficulties or the prescribed dose cannot be achieved with tablets (documentation required).

Applies to both initial and continuing therapy; documentation required for exceptions.

Deferasirox (Exjade/Jadenu) Coverage

Covered when ALL of the following are met for deferasirox (Exjade/Jadenu):

Transfusion-related iron overload: A) Initial Therapy: patient receives regular blood transfusions for a chronic condition AND pre‑treatment serum ferritin >1000 mcg/L AND deferasirox is prescribed by or in consultation with a hematologist. OR B) Patients currently receiving deferasirox: patient is benefiting from therapy (e.g., reduction in serum ferritin, stable disease, reduced organ iron load) as documented by the prescribing physician.see node text

Approve for 1 year when criteria are met.

NTDT indication: A) Initial Therapy: non‑transfusion‑dependent thalassemia (NTDT) patients with pre‑treatment serum ferritin >300 mcg/L AND deferasirox is prescribed by or in consultation with a hematologist. OR B) Patients currently receiving deferasirox for NTDT: patient is benefiting from therapy (e.g., reduction in serum ferritin, stable disease, reduced organ iron load) as documented by the prescribing physician.see node text

NTDT criteria reflect FDA‑labeled indications (approval duration typically 1 year).

Non‑Covered/Not Recommended Uses

Conditions not recommended for approval

Not recommended: Coverage is not recommended for uses not listed in the Recommended Authorization Criteria. Deferasirox and deferiprone have not been shown effective, or have limited/preliminary data or potential safety concerns, for other conditions; this list is not exhaustive.

Criteria will be updated as new published data are available.

Coverage is not recommended for uses that are not specifically listed in the Recommended Authorization Criteria. The list of covered indications in this policy represents the conditions for which authorization has been defined; it is not exhaustive and will be updated if new published data support additional indications.

Uses of deferasirox or deferiprone that lack evidence of efficacy, have only limited or preliminary data, or raise potential safety concerns are considered not recommended for approval. Such uses outside the listed authorization criteria may be treated as not medically necessary unless future data justify coverage.

Clinical Thresholds and Key Values

Serum ferritin

Transfusion-related iron overload ferritin threshold> 1000 mcg/L (pre-treatment serum ferritin required for initial chelation approval)

NTDT ferritin threshold> 300 mcg/L (pre-treatment serum ferritin for NTDT deferasirox indication)

Documentation notePre-treatment serum ferritin must be documented when seeking approval for chelation therapy

Liver iron concentration (LIC)

LIC threshold for NTDT>= 5 mg Fe/g dw (liver iron concentration required for deferasirox NTDT indication)

PurposeLIC used to establish eligibility for deferasirox in non‑transfusion‑dependent thalassemia per FDA‑approved labeling

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Exjade/Jadenu (deferasirox) and Ferriprox (deferiprone) prior to pharmacy benefit coverage. Typical approval duration is 1 year for both initial and continuation therapy when criteria are met. Initial prescriptions must be by or in consultation with a hematologist or a physician who specializes in the treated condition.

Prior authorization required for Exjade/Jadenu and Ferriprox
Typical approval duration: 1 year (initial and continuation when criteria met)
Initial prescribing by or in consultation with a hematologist or specialist is required

Prior Authorization

Brand vs Generic Requirements

Brand Ferriprox (brand deferiprone or oral solution) will only be approved when one of the following is documented: trial and failure of or intolerance to generic deferiprone tablets; a clinically significant allergy or serious adverse reaction attributed to an inactive ingredient in the generic product (documentation required); or inability to swallow tablets / inability to attain the prescribed dose with tablets (documentation required).

Clinical Background

Exjade/Jadenu (deferasirox) and Ferriprox (deferiprone) are oral iron chelators indicated for management of chronic iron overload. They are typically used to reduce serum ferritin and liver iron concentration in patients with transfusion-related iron overload; deferasirox also has a labeled indication for certain patients with non‑transfusion‑dependent thalassemia. Approvals and continued use are generally based on demonstration of benefit such as reduction in serum ferritin or stabilization/reduction in organ iron burden rather than direct evidence of improved survival.

Key Definitions

Transfusion‑related iron overload

DefinitionChronic iron accumulation from repeated blood transfusions (transfusion‑related iron overload)

Illustrative transfusion thresholdExample: ~20 units of packed red blood cells for a 40 kg person as evidence of chronic transfusional iron overload

Alternate markerConsistently elevated serum ferritin > 1000 mcg/L may be used as evidence of transfusion‑related iron overload

Non‑transfusion‑dependent thalassemia (NTDT)

DefinitionThalassemia syndromes not regularly transfused (non‑transfusion‑dependent thalassemia, NTDT)

Deferasirox age requirementAge ≥ 10 years for NTDT indication

Policy Summary

Payermedical mutual - ohio

PolicyOral iron chelators (deferasirox, deferiprone) — Prior authorization and coverage criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateJun 19, 2025

Key ActionObtain prior authorization and document pre-treatment serum ferritin and prescribing physician specialty (hematologist) for approval.

SourceLink

On This Page

Documentation noteLIC measurement should be documented when applying NTDT criteria for deferasirox

Brand Ferriprox requires prior trial/failure or intolerance to generic deferiprone tablets unless an exception applies
Exceptions: documented significant allergy to generic inactive ingredient(s) OR inability to swallow tablets / dosing not attainable with tablets — documentation required
Brand oral solution may be approved for dysphagia or dosing needs if documented

Documentation Required

Required Documentation

Providers must supply documentation to support medical necessity. Required pretreatment laboratory documentation and records must be available and may be requested as part of the review. The Company may request additional records and will deny when services are not medically necessary, investigational/experimental, outside member benefits, or when billing/practice patterns are inappropriate or excessive.

Pre-treatment serum ferritin level documentation (typically >1,000 mcg/L for transfusion-dependent; >300 mcg/L for non-transfusion-dependent where applicable)
Evidence of benefit for continuation requests (e.g., reduction in serum ferritin, stable disease, reduced organ iron load) as stated by the prescribing physician
If brand Ferriprox requested, documentation of failure/intolerance to generic deferiprone or documentation supporting an allowed exception (allergy to inactive ingredient or inability to swallow / dose attainment)
Prescribing physician specialty documentation (hematologist or specialist) or documentation of consultation
Additional records, test results, and provider credentials as requested by the Company

Denial Risk

Denial Triggers

Denials may be issued for requests that do not meet the policy criteria, are investigational/experimental, lack required documentation, or fall outside the member's benefit coverage. Typical denial rationales include: absence of required pretreatment ferritin levels, lack of specialist involvement/consultation, failure to document trial of generic before brand Ferriprox (when required), or insufficient evidence of benefit for continuation.

Not medically necessary: does not meet the clinical criteria in this policy
Investigational/experimental: uses not listed in the policy without supporting evidence
Insufficient documentation: missing serum ferritin, lack of documentation for brand exceptions, or missing provider specialty/consultation notes
Out-of-scope/benefit exclusions or patterns of inappropriate/excessive billing

Deferasirox LIC & ferritin eligibilityLIC ≥ 5 mg Fe/g dw and serum ferritin > 300 mcg/L required for deferasirox NTDT indication

Documentation noteLIC and pre‑treatment serum ferritin must be documented per FDA‑approved NTDT criteria